Navigation Links
John P. Cogswell, Ph.D., receives 2009 Alzheimer Award

May 26, 2009, Amsterdam, The Netherlands and San Antonio, TX, USA John P. Cogswell, PhD, has been chosen as the recipient of the 2009 Alzheimer Award presented by the Journal of Alzheimer's Disease in recognition of his outstanding work, "Identification of miRNA changes in Alzheimer's disease brain and CSF yields putative biomarkers and insights into disease pathways" (J Alzheimers Dis 14: 27-41, 2008) by J.P. Cogswell et al.

"My co-authors and I are extremely pleased to have been chosen by a distinguished group of our peers as the recipients of this year's Journal of Alzheimer's Disease award for our work on the use of biomarkers in the diagnosis of AD," said Dr. Cogswell.

Each year the Associate Editors of the Journal of Alzheimer's Disease select an outstanding article from the previous year's volume to receive this prestigious award, which is made possible by support from IOS Press and Elan Pharmaceuticals. Dr. Cogswell will be presented with the bronze Alzheimer Medal with the likeness of Alois Alzheimer and a cash award.

Dr. Cogswell's work examines changes in microRNA expression and their role in the sporadic form of the disease. MicroRNAs are small regulatory RNAs that affect many basic cellular and biological processes. They are best known for regulating RNA and protein expression in pathways and networks due to the combinatorial binding potential between microRNAs and their targets. Using a sensitive and specific qRT-PCR technology this paper demonstrates altered expression of specific microRNAs in the brain of Alzheimer's disease (AD) subjects. The changes were both dependent and independent of the pathological changes with some detected quite early in the disease. Many of the microRNAs have functional roles in known AD pathways including neuronal differentiation, glutamate, and innate immunity although the potential combinatorial effects on insulin signaling were noteworthy.

Because of the need for diagnostic biomarkers of disease progression this paper additionally examines the microRNAs in the cerebrospinal fluid of late stage AD patients. Again AD-specific changes were detected although here microRNAs with known and potential combinatorial effects on T lymphocyte signaling and inflammation pathways were identified. Because the CSF contains memory T cells and antigen presenting cells involved in immune-surveillance of the brain, these data suggested that microRNA responses in CSF cells might be sentinels of the disease.

"More work is required to validate whether these changes are specific to AD, can be used to follow the course of AD or overlap with other neurodegenerative diseases involving inflammation," stated Dr. Cogswell. "However, the data highlight the potential of microRNAs to further understand sporadic Alzheimer's disease and provide accessible biomarkers to aid clinical diagnosis."

Dr. Cogswell, a former researcher at GlaxoSmithKline Inc., Research Triangle Park, NC, received his initial training from Duke University, Durham, North Carolina followed by postdoctoral fellowships in cellular and molecular immunology at the University of California, Los Angeles and University of North Carolina, Chapel Hill. In 16 years at GSK, Dr. Cogswell and colleagues developed high content qRT-PCR and histology applications that identified tractable targets from the human genome sequencing project and transcriptional biomarkers that decreased attrition in drug discovery.


Contact: Astrid Engelen
IOS Press

Related medicine news :

1. Sally L. Glaser, Ph.D., Named CEO of the Northern California Cancer Center
2. Barry Arbuckle, Ph.D., President & CEO of MemorialCare Medical Centers to Chair Southern California March for Babies 2009, March of Dimes Largest Fundraising Events
3. Exagen Diagnostics Names John Alsobrook, Ph.D., Vice President and Chief Operating Officer
4. Jan Ake Gustafsson, M.D., Ph.D., Joins Bionovos Scientific Advisory Board
5. SCOLR Pharma, Inc. Announces Appointment of Bruce S. Morra, Ph.D., as President & CEO
6. Light Sciences Oncology Elects Former FDA Commissioner Frank Young, M.D., Ph.D., to Board of Directors
7. Daniel J. Nevrivy, Ph.D., Biotech and Pharmaceutical Patent Attorney, Launches New Law Firm Aimed at Helping Clients Preserve Their Capital
8. BioNanomatrix Appoints Gary Zweiger, Ph.D., as Vice President of Business Development
9. Alexander R. Giaquinto, Ph.D., Joins Regado Biosciences as Senior Vice President of Regulatory Affairs and Quality Assurance
10. Human Genome Sciences Appoints John L. Lamattina, Ph.D., to Its Board of Directors
11. Conatus Pharmaceuticals Appoints Anthony W. Fox, MD, Ph.D., as Chief Medical Officer
Post Your Comments:
(Date:12/1/2015)... , ... December 01, 2015 , ... ... Visage Imaging Inc. (“Visage”), a wholly owned subsidiary of Pro Medicus Ltd. (ASX: ... enhancements at the Radiological Society of North America (RSNA) 2015 annual meeting through ...
(Date:12/1/2015)... ... ... Lutronic, a leading innovator of aesthetic and medical laser and energy-based technology, ... in the United States. Clarity is a Superior Dual Wavelength Platform which combines ... single platform that is easy to own and operate. , For over a ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... SACC-GA and SACC-USA through membership and leadership since 2008. Gary Bruce, President ... SACC-USA . Gary has spent a significant amount of time in Sweden ...
(Date:12/1/2015)... ... December 01, 2015 , ... SonaCare Medical ... HSJ Acute Sector Innovation Award on November 18th. This prestigious award recognizes annually ... propose exciting enhancements to the medical landscape. , The UCLH team won the ...
(Date:11/30/2015)... ... 2015 , ... Trevor and Taylor Crabb have unveiled an exciting new ... represent the United States. This hybrid crowdfunding campaign is designed to provide ... in addition to offering corporate sponsors with some great marketing deliverables with the brothers ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... Va. , Dec. 1, 2015  AccuTEC ... unveiled a new corporate logo and brand identity ... the design and engineering of bladed products where ... --> --> Serving manufacturers ... glass, and auto glass equipment, AccuTEC,s product lines ...
(Date:12/1/2015)... months of adjunctive metformin therapy does not improve glycemic outcomes ... research from T1D Exchange and funded by the ... on measures of obesity, including weight and BMI. The results, ... the American Medical Association , are from the largest clinical ... and obese adolescents with type 1 diabetes. ...
(Date:12/1/2015)... N.J. , Dec. 1, 2015 ... held in San Francisco, CA ... solutions to the coronary marketplace. During a satellite ... in Stent Design to Minimize Restenosis", a renowned ... currently available Medinol NIRxcell™ CoCr Coronary Stent System ...
Breaking Medicine Technology: